Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anastrozole + AZD4547
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Anastrozole + AZD4547 is a combination therapy investigated for the treatment of estrogen receptor positive (ER+) breast cancer. AZD4547 is a potent and selective inhibitor of Fibroblast Growth Factor Receptor (FGFR)-1, 2, and 3 receptor tyrosine kinases that was studied in combination with the aromatase inhibitor anastrozole. This combination was specifically designed to address endocrine resistance in patients who had progressed on aromatase inhibitor therapy. The RADICAL trial investigated this combination in patients with ER+ metastatic breast cancer who had become resistant to aromatase inhibitors.
- Other names
- fexagratinib + letrozoleAZD4547 + anastrozoleAZD4547 + letrozoleAZD4547 / anastrozole or letrozolefexagratinib + anastrozole or letrozole
02
Targets
CYP19A1 (Aromatase)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)
Beyond the preview
Go deeper on anastrozole + AZD4547.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anastrozole + AZD4547.